Monte Rosa Therapeutics (GLUE) Prepaid Assets (2020 - 2026)
Monte Rosa Therapeutics (GLUE) recorded quarterly Prepaid Assets of $6.7 million in Q1 2026, up 49.92% quarter-over-quarter from $4.5 million in Q4 2025, and up 40.02% on a YoY basis from $4.8 million in Q1 2025.
Monte Rosa Therapeutics (GLUE) Prepaid Assets (2020 - 2026) Analysis & Trends
Monte Rosa Therapeutics' Prepaid Assets history runs 7 years deep, the most recent figure standing at $6.7 million for Q1 2026.
- In Q1 2026, Prepaid Assets rose 40.02% year-over-year to $6.7 million; the TTM figure through Mar 2026 stood at $6.7 million (up 40.02% YoY), while the FY2025 annual figure was $4.5 million, down 12.45% from the prior year.
- Prepaid Assets was $6.7 million for Q1 2026 at Monte Rosa Therapeutics, up from $4.5 million in the prior quarter.
- In the past five years, Prepaid Assets ranged from a high of $8.4 million in Q3 2024 to a low of $2.9 million in Q2 2022.
- Historically, Prepaid Assets has averaged $5.0 million across 5 years, with a median of $4.8 million in 2025.
- The sharpest annual moves came in 2022 and 2025: Prepaid Assets surged 135.96% in 2022, then tumbled 33.61% in 2025.
- A 5-year view of Prepaid Assets shows it stood at $4.4 million in 2022, then fell by 25.88% to $3.3 million in 2023, then jumped by 55.37% to $5.1 million in 2024, then slipped by 12.45% to $4.5 million in 2025, then jumped by 49.92% to $6.7 million in 2026.
- The last three Prepaid Assets figures came in at $6.7 million (Q1 2026), $4.5 million (Q4 2025), and $5.6 million (Q3 2025), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Alterity Therapeutics | 925,601.88 Bn | 925,601.85 Bn | - |
| 2 | Belite Bio | 58,560.00 Bn | 58,560.00 Bn | - |
| 3 | Quantum Biopharma | 17,284.41 Bn | 17,284.40 Bn | - |
| 4 | Legend Biotech | 2,809.00 Bn | 2,808.71 Bn | 242.10 Mn |
| 5 | Evaxion A | 1,334.43 Bn | 1,334.42 Bn | - |
| 6 | Akari Therapeutics | 1,312.27 Bn | 1,312.26 Bn | - |
| 7 | Psyence Biomedical | 212.16 Bn | 212.16 Bn | - |
| 8 | Vertex Pharmaceuticals | 114.83 Bn | 107.58 Bn | 2.59 Bn |
| 9 | Abivax | 91.96 Bn | 91.96 Bn | - |
| 10 | Monte Rosa Therapeutics | 1.83 Bn | 1.15 Bn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 6.72 Mn |
| Dec 31, 2025 | 4.48 Mn |
| Sep 30, 2025 | 5.59 Mn |
| Jun 30, 2025 | 6.50 Mn |
| Mar 31, 2025 | 4.80 Mn |
| Dec 31, 2024 | 5.12 Mn |
| Sep 30, 2024 | 8.43 Mn |
| Jun 30, 2024 | 5.85 Mn |
| Mar 31, 2024 | 5.54 Mn |
| Dec 31, 2023 | 3.29 Mn |
| Sep 30, 2023 | 4.14 Mn |
| Jun 30, 2023 | 3.88 Mn |
| Mar 31, 2023 | 5.69 Mn |
| Dec 31, 2022 | 4.44 Mn |
| Sep 30, 2022 | 4.57 Mn |
| Jun 30, 2022 | 2.90 Mn |
| Mar 31, 2022 | 3.20 Mn |
| Dec 31, 2021 | 2.60 Mn |
| Sep 30, 2021 | 3.49 Mn |
| Jun 30, 2021 | 1.23 Mn |